Biogen Idec Inc (NASDAQ:BIIB) and AbbVie (NYSE: ABBV) announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process (DAC HYP) when compared to intramuscular interferon beta-1a (IFN β-1a), as a potential treatment for relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Results showed that DAC HYP was superior on the study’s primary endpoint, demonstrating a statistically significant 45 percent reduction in annualized relapse rate (ARR) compared to IFN β-1a (p<0.0001). Biogen Idec Inc (NASDAQ:BIIB) net profit margin is 25.00% and weekly performance is -2.38%. On last trading day company shares ended up $309.98. Analysts mean target price for the company is $348.64. Biogen Idec Inc (NASDAQ:BIIB) distance from 50-day simple moving average (SMA50) is 4.07%.
On 11 JUNE Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced that on June 11, 2014, two scientific posters associated with its study of NBI-98854 in Phase IIb clinical trials of tardive dyskinesia patients, will be presented at the 2014 Annual Congress of Parkinson’s Disease and Movement Disorders in Stockholm Sweden. This annual meeting brings together over 5,000 clinicians and scientists from around the world to address current topics related to movement disorders. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) shares fell -1.45% in last trading session and ended the day on $14.97. NBIX return on assets is -23.60%. Neurocrine Biosciences, Inc. (NASDAQ:NBIX) quarterly performance is -11.89%.
On 22 MAY ANI Pharmaceuticals Inc (NASDAQ:ANIP) reported $0.33 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.32 by $0.01. The company had revenue of $10.90 million for the quarter, compared to the consensus estimate of $11.40 million. During the same quarter in the previous year, the company posted ($0.18) earnings per share. The company’s revenue for the quarter was up 94.6% on a year-over-year basis. On average, analysts predict that ANI Pharmaceuticals will post $1.74 earnings per share for the current fiscal year. ANI Pharmaceuticals Inc (NASDAQ:ANIP) shares moved down -0.49% in last trading session and was closed at $34.20, while trading in range of $33.12 – $34.67. ANI Pharmaceuticals Inc (NASDAQ:ANIP) year to date (YTD) performance is 70.32%.
Repros Therapeutics Inc (NASDAQ:RPRX) ended the last trading day at $16.05. Company weekly volatility is calculated as 4.03% and price to cash ratio as 5.45. Repros Therapeutics Inc (NASDAQ:RPRX) showed a negative weekly performance of -2.31%.
On 4 JUNE Auspex Pharmaceuticals Inc (NASDAQ:ASPX) said it will present at the Jefferies 2014 Global Healthcare Conference in New York City. Auspex Pharmaceuticals Inc (NASDAQ:ASPX) weekly performance is -4.50%. On last trading day company shares ended up $20.15. Analysts mean target price for the company is $38.75. Auspex Pharmaceuticals Inc (NASDAQ:ASPX) distance from 50-day simple moving average (SMA50) is -7.12%.